<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="172802">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00846560</url>
  </required_header>
  <id_info>
    <org_study_id>ALS04CTIL</org_study_id>
    <nct_id>NCT00846560</nct_id>
  </id_info>
  <brief_title>Involvement of Lymphocyte Type B in Amyotrophic Lateral Sclerosis (ALS)</brief_title>
  <official_title>Involvement of Lymphocyte Type B in Amyotrophic Lateral Sclerosis (ALS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rambam Health Care Campus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rambam Health Care Campus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The involvement of Lymphocyte type B in Amyotrophic lateral sclerosis (ALS) patients will be
      compared to lymphocyte in healthy subjects.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date>August 2008</start_date>
  <primary_completion_date type="Anticipated">December 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>1 ALS patients</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>2 Healthy subjects</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Amyotrophic lateral sclerosis and Healthy subjects
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ALS patients who could sign ICF.

        Exclusion Criteria:

          -  No ALS patients age less than 18 years.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Rambam Medical center, Neurology Department</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>February 2009</verification_date>
  <lastchanged_date>February 17, 2009</lastchanged_date>
  <firstreceived_date>February 15, 2009</firstreceived_date>
  <responsible_party>
    <name_title>Prof. David Yarnitsky</name_title>
    <organization>Rambam medical center</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
